Collaboration And LicensingEntera Bio and OPKO Health have entered into a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic disorders.

Funding And Financial SupportOPKO purchased roughly 3.7 million ordinary shares of Entera for $8 million, providing funding for Entera's share of the development costs.

Market OpportunityThe collaboration with OPKO provides access to a promising anti-obesity candidate, funding, and favorable economics in a large and lucrative market.

Bears Say

Clinical Development RisksRisks include failure to advance EB613 or EB612 through clinical development in a timely manner and inability to secure a partner to optimize the commercial value of EB613.

Financial PerformanceEntera reported a net loss per share mainly driven by higher than expected operating expenses.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

2.02% Insiders

0.05%

Mutual Funds

14.36% Other Institutional Investors

83.57% Public Companies and Individual Investors

Detailed Ownership Overview >

5DT FAQ

What was Entera Bio’s price range in the past 12 months?

Entera Bio lowest stock price was €1.29 and its highest was €2.58 in the past 12 months.

What is Entera Bio’s market cap?

Entera Bio’s market cap is €76.62M.

When is Entera Bio’s upcoming earnings report date?

Entera Bio’s upcoming earnings report date is Aug 08, 2025 which is in 43 days.

How were Entera Bio’s earnings last quarter?

Entera Bio released its earnings results on May 09, 2025. The company reported €0.054 earnings per share for the quarter, beating the consensus estimate of -€0.063 by €0.116.

Is Entera Bio overvalued?

According to Wall Street analysts Entera Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Entera Bio pay dividends?

Entera Bio does not currently pay dividends.

What is Entera Bio’s EPS estimate?

Entera Bio’s EPS estimate is -0.1.

How many shares outstanding does Entera Bio have?

Entera Bio has 45,452,168 shares outstanding.

What happened to Entera Bio’s price movement after its last earnings report?

Entera Bio reported an EPS of €0.054 in its last earnings report, beating expectations of -€0.063. Following the earnings report the stock price went up 0.529%.

Which hedge fund is a major shareholder of Entera Bio?

Currently, no hedge funds are holding shares in DE:5DT

Entera Bio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-71.46%

Trailing 12-Months

Asset Growth

110.96%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Entera Bio

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.